# Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

> **NCT05284539** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 760 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab

## Key facts

- **NCT ID:** NCT05284539
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-10-10
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284539, "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT05284539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*